1 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU2 Servicio de Oncología Médica, Hospital Ramón y Cajal, Carretera de Colmenar Viejo Km. 9.100, 28034, Madrid, Spain, firstname.lastname@example.org unknown4 Oncology, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms, effective management of related adverse events (AEs) is vital to ensure patient compliance and maximize clinical benefit with vandetanib therapy.
Advances in Therapy, 2013, Vol 30, Issue 11, p. 945-66